Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yinqi Sanhuang Decoction plus entecavir for hepatitis B-related compensated cirrhosis
ChiCTR1900021532Phase 3Recruiting
- Sponsor
- China Academy of Chinese Medical Sciences
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Yinqi Sanhuang Decoction and entecavir in hepatitis B-related liver cirrhosis (2 arms), sponsored by China Academy of Chinese Medical Sciences. Primary endpoint: Annual incidence of liver cancer. Started Jan 2019; status: recruiting.
02
Drugs
Yinqi Sanhuang Decoctionentecavir
03
Conditions
hepatitis B-related liver cirrhosis
Beyond the preview
Go deeper on ChiCTR1900021532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021532.